Zinc Acetate to Improve Chronic Cough (ZICO)
The American Lung Association Airways Clinical Research Center (ACRC) network is evaluating measurements of cough symptoms and the impact of cough on quality of life for people with chronic cough. A chronic cough is a cough that lasts at least 8 weeks, but often much longer. Chronic cough is common, affecting 9-12% of the population. It can have a negative impact on quality of life and may lead to social isolation, lack of sleep, and chronic fatigue. Some people find that their chronic cough gets better when they take medicines for asthma, gastroesophageal reflux (GERD), or sinus problems. However, some people are not helped by these or other medicines. People with a cough that does not respond to treatments is said to have chronic refractory cough. The Pilot of Zinc Acetate to Improve Chronic Cough (ZICO) study is being done to see if zinc acetate is safe and tolerable to use in treating chronic refractory cough. The measures include a daily cough assessment, or cough diary, breathing and blood tests, and questionnaires. ZICO is a 9-week study with 5 clinic visits and 1 phone visit. Patients will be asked to fill out a daily Cough Diary while in the study. The ACRC is looking for men or women age 18 or older with chronic cough to enroll in the ZICO study at three ACRC clinical centers: Duke University (North Carolina), National Jewish Health (Colorado), and Mt. Sinai Medical Center (New York). In addition, a larger trial, the Chronic Refractory Cough Cohort study (COCO) is being done at all ALA ACRC clinical centers. COCO will evaluate different measures of cough, including its effect on quality of life. Results of COCO and ZICO will be used to develop a full-scale trial to test treating chronic cough with zinc acetate.
September 1, 2016 - June 30, 2019